Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
163.24B
Market cap163.24B
Price-Earnings ratio
10.42
Price-Earnings ratio10.42
Dividend yield
3.39%
Dividend yield3.39%
Average volume
17.73M
Average volume17.73M
High today
$37.42
High today$37.42
Low today
$35.53
Low today$35.53
Open price
$36.29
Open price$36.29
Volume
20.60M
Volume20.60M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.53
52 Week low$35.53

NVO News

Nasdaq 4h
Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill

(RTTNews) - Hims & Hers Health Inc. (HIMS) announced that a wide range of Novo Nordisk's FDA-approved GLP-1 medications are now available to eligible customers....

Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill
TipRanks 6h
Novo Nordisk says Awiql approved by FDA in type 2 diabetes patients

The company states: “Novo Nordisk (NVO) announced that the FDA has approved Awiqli injection 700 units/mL, the first and only once-weekly, long-acting basal ins...

TipRanks 12h
Novo Nordisk AGM Backs 2025 Dividend, Expands Capital Mandates and Refreshes Board

The latest update is out from Novo Nordisk ( (NVO) ). Novo Nordisk held its Annual General Meeting in Bagsværd, Denmark, on 26 March 2026, approving the 2025 s...

Analyst ratings

61%

of 36 ratings
Buy
30.6%
Hold
61.1%
Sell
8.3%

More NVO News

Seeking Alpha 13h
Novo Nordisk adds Mars CEO as board observer

In its annual general meeting on Thursday, Novo Nordisk (NVO) announced the appointment of Poul Weihrauch, CEO of U.S. chocolate maker Mars, as an observer to t...

Novo Nordisk adds Mars CEO as board observer
TipRanks 14h
Novo Nordisk announces resolutions from annual meeting

Novo Nordisk (NVO) announces the resolutions at its annual meeting. The company received authorization until the annual meeting in 2027 to repurchase its own sh...

Bloomberg 1d
Novo Chairman Faces Testy Investors With Little Progress So Far

Novo Nordisk A/S’s Chairman Lars Rebien Sorensen will face investors at the company’s annual meeting for the first time on Thursday after his boardroom coup. He...

Novo Chairman Faces Testy Investors With Little Progress So Far
Simply Wall St 1d
Novo Nordisk’s Recent Momentum Shift Prompts Fresh Look At Valuation Gap

Advertisement How Novo Nordisk’s recent performance sets up the current valuation debate Novo Nordisk (NYSE:NVO) has recently seen weak share price performanc...

Novo Nordisk’s Recent Momentum Shift Prompts Fresh Look At Valuation Gap
Nasdaq 2d
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data

Novo Nordisk NVO and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China...

NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Benzinga 2d
Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?

Semaglutide is a key ingredient in the famed Wegovy and Ozempic. UBT251 Shows Superior Glycemic Control And Weight Loss The once-weekly injectable UBT251 targ...

Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?
Nasdaq 3d
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer

Key Points Regulators recently approved Wegovy HD, which is a higher-dose version of its popular weight loss drug. Wegovy HD helped people lose 20.7%, on aver...

Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.